Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults

LAUR Repository

Show simple item record

dc.contributor.author Kabbara, Wissam K.
dc.contributor.author Ramadan, Wijdan H.
dc.date.accessioned 2016-10-03T06:28:51Z
dc.date.available 2016-10-03T06:28:51Z
dc.date.copyright 2015 en_US
dc.date.issued 2016-10-03
dc.identifier.issn 1876-0341 en_US
dc.identifier.uri http://hdl.handle.net/10725/4480
dc.description.abstract This paper reviews the current literature and information on the combination drug Complera™ (rilpivirine/emtricitabine/tenofovir disoproxil fumarate) that was approved by the Food and Drug Administration (FDA) in August 2011. PubMed, Cochrane and Embase (2001–2014) were searched for primary and review articles on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate, individually or in combination. Data from drug manufacturer and product label was also used. Clinical trial reports were selected, extracted and analyzed to include relevant and recent ones. Selected English-language trials were limited to those with human subjects and included both safety and efficacy outcomes. Results from two phase 3 randomized double blind trials (ECHO and THRIVE) showed that rilpivirine is non-inferior to efavirenz in suppressing viral load below 50 copies/mL in anti-retroviral therapy (ART) naïve human immunodeficiency virus (HIV) infected patients. In addition, psychiatric disturbances, rash and increase in lipid levels occurred less frequently with rilpivirine when compared to efavirenz. However, virological failure and drug resistance were higher with rilpivirine in patients with baseline viral load >100,000 copies/mL. Rilpivirine showed cross resistance to efavirenz and etravirine. Efavirenz, on the other hand, did not demonstrate cross resistance to rilpivirine and etravirine, leaving the latter drugs as options for use in case of virological failure with efavirenz. Complera™ remains an acceptable alternative treatment to Atripla™ in ART naïve patients who have a pre-ART plasma HIV RNA <100,000 copies/mL and CD4 count >200 cells/mm3 with non-inferior efficacy and better safety and tolerability. en_US
dc.language.iso en en_US
dc.title Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 200104485 en_US
dc.author.department Pharmacy Practice en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of Infection and Public Health en_US
dc.journal.volume 8 en_US
dc.journal.issue 5 en_US
dc.article.pages 409-417 en_US
dc.keywords Emtricitabine en_US
dc.keywords Rilpivirine en_US
dc.keywords Tenofovir disoproxil fumarate en_US
dc.keywords Complera en_US
dc.keywords HIV en_US
dc.identifier.doi http://dx.doi.org/10.1016/j.jiph.2015.04.020 en_US
dc.identifier.ctation Kabbara, W. K., & Ramadan, W. H. (2015). Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. Journal of infection and public health, 8(5), 409-417. en_US
dc.author.email wissam.kabbara@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://www.sciencedirect.com/science/article/pii/S1876034115000878 en_US
dc.orcid.id https://orcid.org/0000-0002-7310-9192 en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account